

Date and Time: *Friday 31 May 2013, 10:00-16:00*

Minutes: Final

Guideline Development Group Meeting 7 Lipid Modification (update)

Place: *Boardroom, National Clinical Guideline Centre
180 Great Portland Street, London W1W 5QZ*

Present:

Anthony Wierzbicki (Chair)	(Present for notes 1 – 7)
Rajai Ahmad (Cardiologist)	(Present for notes 1 – 7)
Lindsay Banks (Pharmacist)	(Present for notes 1 – 7)
Liz Clark (Patient/carer member)	(Present for notes 1 – 7)
Martin Duerden (General practitioner)	(Present for notes 1 – 7)
Eleanor Grey (Patient/carer member)	(Present for notes 1 – 7)
Michael Khan (Diabetologist)	(Present for notes 1 – 7)
Emma McGowan (Nurse)	(Present for notes 1 – 7)
Dermot Neely (Chemical pathologist and lipidologist)	(Present for notes 1 – 7)
Nadeem Qureshi (General practitioner)	(Present for notes 1 – 7)
Alan Rees (Metabolic/general medicine/elderly care physician)	(Present for notes 1 – 7)
David Wald (Cardiologist)	(Present for notes 1 – 7)
Gary Collins (Co-opted member)	(Present for notes 1 – 4)
Angela Cooper (Senior research fellow)	(Present for notes 1 – 4)
Lina Gulhane (Joint head of information science)	(Present for notes 6 – 7)
Martin Harker (Health economist)	(Present for notes 1 – 7)
Vanessa Nunes (Guideline lead and senior research fellow)	(Present for notes 1 – 7)
Silvia Rabar (Senior project manager and research fellow)	(Present for notes 1 – 7)

In attendance:

NICE Staff:		
-------------	--	--

Observers:

Smita Padhi	(Present for notes 1 – 4)
Stephanie Mills	(Present for notes 1 – 7)
Mayret Castillo	(Present for notes 1 – 4)
Elizabeth Rouncefield	(Present for notes 6 – 7)

Notes

1. The Chair welcomed the group to the seventh meeting of this GDG. Apologies were received from Rajai Ahmad, Alan Rees, Norma O'Flynn, David Wonderling and Caroline Keir. The Chair asked all GDG members to declare any relevant conflicts of interest. The following interests were declared
 - 1.1. Alan Rees:
Personal pecuniary interest: I have recently attended an Advisory Board for Lomitapide for which I received an honorarium. This drug is not licensed for use at present and is not considered in the NICE guideline we are currently developing. I have also attended an Advisory Board for Aegerion who are developing a monoclonal antibody for PCSK9. I also received an honorarium for this. However this is not licensed as yet and again is not under consideration for the current NICE guidelines.
 - 1.2. Anthony Wierzbicki:
Personal non-pecuniary interest: Publications on CVD risk assessment 2003-2008. Member, London SE & SW Cardiac Network Groups (NHS checks) 2008-13.
 - 1.3. David Wald:
Personal non-pecuniary interest: Principal investigator for a trial of combination treatment for prevention of CVD; Wald DS, Morris JK, Wald NJ (2012) Randomized Polypill Crossover Trial in People Aged 50 and Over. PLoS ONE 7(7): e41297. doi:10.1371/journal.pone.0041297.
 - 1.4. Dermot Neely:
Personal pecuniary interest: I have been invited by Sanofi UK & Ireland to participate in the UK Lipid Strategic Advisory Board to be held on Friday 12th April 2013, regarding a new product in development for treatment of hypercholesterolaemia, for which I will receive an honorarium.
Non-personal pecuniary interest: Newcastle upon Tyne Hospitals NHS Foundation Trust /Newcastle University Clinical Research Facility participates in commercial clinical trials including those of novel lipid lowering therapy for Familial Hypercholesterolaemia, for which I have had responsibility for recruiting some of the eligible patients.
Personal non-pecuniary interest: I am a Trustee and Board member of HEART UK the Cholesterol Charity and Co-Chairman of the Familial Hypercholesterolaemia Guideline Implementation Group, a multi-disciplinary team which since 2008 has campaigned for the full implementation in England of the NICE Clinical Guideline CG71 and has developed and published a Guideline Implementation Toolkit on the HEART UK Web site.
Since 2002 I have been a member of the FATS Guideline Group, Newcastle and Northumberland which produces local guidance for primary and secondary care cardiovascular risk assessment and lipid management. The most recent version (FATS6) was published on the North East SHA web site. This work is non-remunerated.
I have recently given an educational lecture on emerging therapies for Familial Hypercholesterolaemia at the HEART UK North West Lipid Forum, Manchester, 11th June 2013. The meeting was supported by Sanofi UK & Ireland but I was not remunerated for my participation.
 - 1.5. Nadeem Qureshi:
Supervising a PhD student studying new approaches to assess the role of novel markers on risk prediction algorithms, for example CV and osteoporosis. Published on quality of family history in GP datasets. CV lead for the vascular check programme in Derby city. Publishing a paper with a health economist about target versus universal

Notes

- 1.6. Alan Rees:
Membership of JBS-3 guidelines development group including assessment of risk calculation systems. Membership of groups involved in implementation of CVD assessment risk tools in Wales.
 - 1.7. Michael Khan:
involved in developing several local guidelines in Warwickshire. Published a long time ago on risk of CVD. Currently involved discussion, on behalf of the Midlands, with various organisations, including central government and Heart UK about FH. Involved in risk calculations in cancer.
 - 1.8. Gary Collins:
personal pecuniary interest: In 2008 I (along with Professor Douglas Altman, University of Oxford) was commissioned by the Department of Health to independently verify the validation of QRISK conducted by Hippisley-Cox that was published in Heart and replicate an analysis conducted by the University of East Anglia, who attempted to reproduce the Hippisley-Cox validation published in Heart and failed. The report is available on the Department of Health website.
I am the principal investigator of an MRC funded methodology grant using QRESEARCH and Framingham models as tools to demonstrate methodological aspects on how to validate prediction models, such as sample size requirements, handling of missing data and study design for validation studies.
Personal non-pecuniary interest: I have published numerous papers and editorials on risk assessment tools including independent validations of QRISK, QRISK2 and Framingham published in the BMJ and Primary Care Cardiovascular Journal (these studies received no funding apart from the original validation of QRISK published in the BMJ 2009, which was funded as noted above in by the Department of Health).
I have also independently validated other QRESEARCH models, including models for diabetes, osteoporotic and hip fracture, cancer, statin usage, and kidney disease (all received no funding).
I am Head of Prognosis Methodology at the Centre for Statistics in Medicine, University of Oxford and therefore my main areas of research are in risk prediction, including the reporting of risk prediction models (including the development of reporting guidelines for journals, editors, reviewers and authors), evaluating risk of bias in studies developing and validating risk prediction models, systematic reviews of the methodological conduct and reporting of risk prediction models, developing guidance for authors of systematic reviews of prediction models and statistical and study design issues in developing and validating risk prediction models.
2. The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.
 3. An update was then given to the GDG on progress since the last meeting.
 4. The Chair introduced Silvia Rabar, senior project manager and research fellow at NCGC, and Martin Harker, health economist at NCGC, who gave presentation on risk assessment tools for predicting the risk of CVD events in adults without established CVD (primary prevention) and without diabetes.
The GDG then discussed the evidence presented in relation to this guideline and drafted

Notes

recommendations. The Chair thanked Silvia Rabar and Martin Harker for their presentation.

- 5 The Chair gave a summary presentation on the evidence available for the statins review for prevention of CVD. The GDG discussed the issues presented and agreed the next steps for the statins review.
- 6 The Chair introduced Silvia Rabar, senior project manager and research fellow at NCGC, who presented the protocol for the dietary intervention strategies for prevention of CVD. The GDG discussed the issues presented and agreed the review protocol. The Chair thanked Silvia Rabar for her presentation.
- 7 There were no other businesses to discuss. The Chair closed the meeting and thanked everybody for attending.

Date, time and venue of the next meeting

- 11 September 2013, 10:00-16:00, at the Royal College of Physicians Censors Room, 11 St Andrews Place, London NW1 4LE
- 12 September 2013, 10:00-16:00, at the National Clinical Guideline Centre, Boardroom, 180 Great Portland Street, London W1W 5QZ